Pular para o conteúdo

Rhode Island Joins the Medicaid GLP-1 Cutbacks as Massachusetts Weight-Loss Use Falls 52% — October 05, 2026

5 de outubro de 2026 · 10 min

Notas do episódio

Rhode Island Medicaid stopped covering GLP-1s prescribed only for weight loss on October 1, and new Massachusetts data shows weight-loss use fell 52% after insurers pulled back. Plus Cigna employees pressing their own employer, a physician's case against the compounding market, and semaglutide's benefits across frailty levels.

In this episode
  1. Rhode Island Medicaid Ends Coverage of Wegovy,… — Inkl

    # Rhode Island Medicaid Ends Coverage of Wegovy, Zepbound, and Other GLP-1 Drugs Prescribed Only for Weight Loss Author: Cole Mercer Published: 2026-10-03T12:50:36Z Source: medicaldaily.com Language: en ## Story Rhode Island Medicaid Ends Coverage of Wegovy, Zepbound, and Other GLP-1 Drugs Prescribed Only for Weight Loss Oct 03, 08:50 am EDT [Medical…

  2. GLP-1 use for weight loss plunges 52% in Massachusetts after insurers cut coverage — Morgan Taylor

    Insurers Cut Coverage — GLP‑1 Weight‑Loss Use in Massachusetts Falls 52%, Impacting 112,000 Patients - CRBC News # Insurers Cut Coverage — GLP‑1 Weight‑Loss Use in Massachusetts Falls 52%, Impacting 112,000 Patients Morgan Taylor| The Cool Down Oct 3• 3 min read 2 Save Massachusetts saw a 52% decline in GLP‑1 use for weight loss between 2025 and Q1 2026 after multiple commercial and state…

  3. OAC Calls on Cigna to Listen to Employees and Restore GLP-1 Coverage — PR Newswire

    OAC Calls on Cigna to Listen to Employees and Restore GLP-1 Coverage # OAC Calls on Cigna to Listen to Employees and Restore GLP-1 Coverage Obesity Action Coalition Oct 02, 2026, 08:15 ET TAMPA, Fla., Oct. 2, 2026 /PRNewswire/ -- The Obesity Action Coalition (OAC) is calling on Cigna to listen to its employees and reconsider its decision to end coverage of GLP-1 medications for weight…

  4. I'm an obesity expert and can't wait for the compounding craze to stop | Fortune — Adonis Saremi

    # I'm an obesity expert and can't wait for the compounding craze to stop | Fortune Author: Adonis Saremi Published: 2026-10-03T11:30:00Z Source: fortune.com Language: en ## Story I'm an obesity expert and can't wait for the compounding craze to stop | Fortune # I’m an obesity expert and can’t wait for the compounding craze to stop By Adonis Saremi October 3, 2026, 7:30 AM ET Dr. Adonis…

  5. Semaglutide Demonstrates Benefits Across Frailty Levels | Obesity | JAMA | JAMA Network — Samantha Anderer

    Semaglutide Demonstrates Benefits Across Frailty Levels | Obesity | JAMA | JAMA Network # Semaglutide Demonstrates Benefits Across Frailty Levels Samantha Anderer Article Information Published Online: October 2, 2026 The glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide demonstrated safety and efficacy regardless of frailty status, a study published in JAMA Cardiology…

Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email [email protected].

Todos os episódios de GLP-1 Daily: Ozempic & Wegovy News

Configurações

Exibição

Idioma

Define quais estações você vê primeiro na página inicial.

Histórico

As rádios e episódios ouvidos recentemente e suas últimas buscas ficam só neste navegador.

Avisos

Um aviso rápido quando um podcast que você segue tem um episódio novo. Desative podcasts individuais pelo sino na página deles.

Conta

Salve favoritos – no app e no site.

Atalhos de teclado

/
Abrir busca
Espaço
Reproduzir ou pausar
← →
No player: voltar 15 s, avançar 30 s (episódios) · na fileira: próximo bloco
↑ ↓
Na fileira: alvo dentro do bloco
Home / End
Na fileira: primeiro ou último bloco
Esc
Fechar janela ou menu
?
Esta visão geral
Tocando agora

Ir para a estação

A seguir

    Adicione episódios com “A seguir” – eles tocam depois do episódio atual.